Serial	serial	O	O
studies	studies	O	O
of	of	O	O
auditory	auditory	O	O
neurotoxicity	neurotoxicity	O	S_disease
in	in	O	O
patients	patients	O	O
receiving	receiving	O	O
deferoxamine	deferoxamine	S_chemical	O
therapy	therapy	O	O
.	.	O	O

Visual	visual	O	O
and	and	O	O
auditory	auditory	O	O
neurotoxicity	neurotoxicity	O	S_disease
was	was	O	O
previously	previously	O	O
documented	documented	O	O
in	in	O	O
42	42	O	O
of	of	O	O
89	89	O	O
patients	patients	O	O
with	with	O	O
transfusion-dependent	transfusion-dependent	O	O
anemia	anemia	O	S_disease
who	who	O	O
were	were	O	O
receiving	receiving	O	O
iron	iron	S_chemical	O
chelation	chelation	O	O
therapy	therapy	O	O
with	with	O	O
daily	daily	O	O
subcutaneous	subcutaneous	O	O
deferoxamine	deferoxamine	S_chemical	O
.	.	O	O

Twenty-two	twenty-two	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
affected	affected	O	O
group	group	O	O
had	had	O	O
abnormal	abnormal	O	O
audiograms	audiograms	O	O
with	with	O	O
deficits	deficits	O	O
mostly	mostly	O	O
in	in	O	O
the	the	O	O
high	high	O	O
frequency	frequency	O	O
range	range	O	O
of	of	O	O
4,000	4,000	O	O
to	to	O	O
8,000	8,000	O	O
Hz	hz	O	O
and	and	O	O
in	in	O	O
the	the	O	O
hearing	hearing	O	O
threshold	threshold	O	O
levels	levels	O	O
of	of	O	O
30	30	O	O
to	to	O	O
100	100	O	O
decibels	decibels	O	O
.	.	O	O

When	when	O	O
deferoxamine	deferoxamine	S_chemical	O
therapy	therapy	O	O
was	was	O	O
discontinued	discontinued	O	O
and	and	O	O
serial	serial	O	O
studies	studies	O	O
were	were	O	O
performed	performed	O	O
,	,	O	O
audiograms	audiograms	O	O
in	in	O	O
seven	seven	O	O
cases	cases	O	O
reverted	reverted	O	O
to	to	O	O
normal	normal	O	O
or	or	O	O
near	near	O	O
normal	normal	O	O
within	within	O	O
two	two	O	O
to	to	O	O
three	three	O	O
weeks	weeks	O	O
,	,	O	O
and	and	O	O
nine	nine	O	O
of	of	O	O
13	13	O	O
patients	patients	O	O
with	with	O	O
symptoms	symptoms	O	O
became	became	O	O
asymptomatic	asymptomatic	O	O
.	.	O	O

Audiograms	audiograms	O	O
from	from	O	O
15	15	O	O
patients	patients	O	O
remained	remained	O	O
abnormal	abnormal	O	O
and	and	O	O
four	four	O	O
patients	patients	O	O
required	required	O	O
hearing	hearing	O	O
aids	aids	O	S_disease
because	because	O	O
of	of	O	O
permanent	permanent	O	B_disease
disability	disability	O	I_disease
.	.	O	O

Since	since	O	O
18	18	O	O
of	of	O	O
the	the	O	O
22	22	O	O
patients	patients	O	O
were	were	O	O
initially	initially	O	O
receiving	receiving	O	O
deferoxamine	deferoxamine	S_chemical	O
doses	doses	O	O
in	in	O	O
excess	excess	O	O
of	of	O	O
the	the	O	O
commonly	commonly	O	O
recommended	recommended	O	O
50	50	O	O
mg/kg	mg/kg	O	O
per	per	O	O
dose	dose	O	O
,	,	O	O
therapy	therapy	O	O
was	was	O	O
restarted	restarted	O	O
with	with	O	O
lower	lower	O	O
doses	doses	O	O
,	,	O	O
usually	usually	O	O
50	50	O	O
mg/kg	mg/kg	O	O
per	per	O	O
dose	dose	O	O
or	or	O	O
less	less	O	O
depending	depending	O	O
on	on	O	O
the	the	O	O
degree	degree	O	O
of	of	O	O
auditory	auditory	O	B_disease
abnormality	abnormality	O	I_disease
,	,	O	O
and	and	O	O
with	with	O	O
the	the	O	O
exception	exception	O	O
of	of	O	O
two	two	O	O
cases	cases	O	O
no	no	O	O
further	further	O	O
toxicity	toxicity	O	S_disease
was	was	O	O
demonstrated	demonstrated	O	O
.	.	O	O

Auditory	auditory	O	O
deterioration	deterioration	O	O
and	and	O	O
improvement	improvement	O	O
,	,	O	O
demonstrated	demonstrated	O	O
serially	serially	O	O
in	in	O	O
individual	individual	O	O
patients	patients	O	O
receiving	receiving	O	O
and	and	O	O
not	not	O	O
receiving	receiving	O	O
deferoxamine	deferoxamine	S_chemical	O
,	,	O	O
respectively	respectively	O	O
,	,	O	O
provided	provided	O	O
convincing	convincing	O	O
evidence	evidence	O	O
for	for	O	O
a	a	O	O
cause-and-effect	cause-and-effect	O	O
relation	relation	O	O
between	between	O	O
deferoxamine	deferoxamine	S_chemical	O
administration	administration	O	O
and	and	O	O
ototoxicity	ototoxicity	O	S_disease
.	.	O	O

Based	based	O	O
on	on	O	O
these	these	O	O
data	data	O	O
,	,	O	O
a	a	O	O
plan	plan	O	O
of	of	O	O
management	management	O	O
was	was	O	O
developed	developed	O	O
that	that	O	O
allows	allows	O	O
effective	effective	O	O
yet	yet	O	O
safe	safe	O	O
administration	administration	O	O
of	of	O	O
deferoxamine	deferoxamine	S_chemical	O
.	.	O	O

A	a	O	O
dose	dose	O	O
of	of	O	O
50	50	O	O
mg/kg	mg/kg	O	O
is	is	O	O
recommended	recommended	O	O
in	in	O	O
those	those	O	O
without	without	O	O
audiogram	audiogram	O	O
abnormalities	abnormalities	O	O
.	.	O	O

With	with	O	O
mild	mild	O	O
toxicity	toxicity	O	S_disease
,	,	O	O
a	a	O	O
reduction	reduction	O	O
to	to	O	O
30	30	O	O
or	or	O	O
40	40	O	O
mg/kg	mg/kg	O	O
per	per	O	O
dose	dose	O	O
should	should	O	O
result	result	O	O
in	in	O	O
a	a	O	O
reversal	reversal	O	O
of	of	O	O
the	the	O	O
abnormal	abnormal	O	O
results	results	O	O
to	to	O	O
normal	normal	O	O
within	within	O	O
four	four	O	O
weeks	weeks	O	O
.	.	O	O

Moderate	moderate	O	O
abnormalities	abnormalities	O	O
require	require	O	O
a	a	O	O
reduction	reduction	O	O
of	of	O	O
deferoxamine	deferoxamine	S_chemical	O
to	to	O	O
25	25	O	O
mg/kg	mg/kg	O	O
per	per	O	O
dose	dose	O	O
with	with	O	O
careful	careful	O	O
monitoring	monitoring	O	O
.	.	O	O

In	in	O	O
those	those	O	O
with	with	O	O
symptoms	symptoms	O	O
of	of	O	O
hearing	hearing	O	B_disease
loss	loss	O	I_disease
,	,	O	O
the	the	O	O
drug	drug	O	O
should	should	O	O
be	be	O	O
stopped	stopped	O	O
for	for	O	O
four	four	O	O
weeks	weeks	O	O
,	,	O	O
and	and	O	O
when	when	O	O
the	the	O	O
audiogram	audiogram	O	O
is	is	O	O
stable	stable	O	O
or	or	O	O
improved	improved	O	O
,	,	O	O
therapy	therapy	O	O
should	should	O	O
be	be	O	O
restarted	restarted	O	O
at	at	O	O
10	10	O	O
to	to	O	O
25	25	O	O
mg/kg	mg/kg	O	O
per	per	O	O
dose	dose	O	O
.	.	O	O

Serial	serial	O	O
audiograms	audiograms	O	O
should	should	O	O
be	be	O	O
performed	performed	O	O
every	every	O	O
six	six	O	O
months	months	O	O
in	in	O	O
those	those	O	O
without	without	O	O
problems	problems	O	O
and	and	O	O
more	more	O	O
frequently	frequently	O	O
in	in	O	O
young	young	O	O
patients	patients	O	O
with	with	O	O
normal	normal	O	O
serum	serum	O	O
ferritin	ferritin	O	O
values	values	O	O
and	and	O	O
in	in	O	O
those	those	O	O
with	with	O	O
auditory	auditory	O	B_disease
dysfunction	dysfunction	O	I_disease
.	.	O	O

